Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Receptor-interacting protein kinase 2 (RIPK2) is a serine/threonine-protein kinase essential for both innate and adaptive immune responses. It acts as a key downstream signaling molecule for NOD-like receptors, specifically NOD1 and NOD2, mediating pro-inflammatory signaling by activating NF-κB and MAPK pathways. RIPK2 is involved in cell death regulation, promoting apoptosis and potentially necroptosis. It also promotes autophagy and is phosphorylated upon DNA damage. RIPK2 plays a central role in chronic inflammatory conditions and cancer progression, making it a validated target for small molecules and PROTACs.
Kinase inhibition; targeted degradation via PROTACs
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Receptor-interacting protein kinase 2 (RIPK2).